Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Phase II Study of Envafolimab Combined With Endostar and Nab-paclitaxel Plus Gemcitabine for First-line Treatment of Advanced Pancreatic Cancer

NCT05298020 is registered in ClinicalTrials.gov with The Affiliated Hospital of Xuzhou Medical University as lead sponsor.

NCT NCT05298020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05298020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Phase II Study of Envafolimab Combined With Endostar and Nab-paclitaxel Plus Gemcitabine for First-line Treatment of Advanced Pancreatic Cancer
Lead sponsor
The Affiliated Hospital of Xuzhou Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
April 1, 2022
Completion date
April 1, 2023
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic cancer